Plasmacytoid variant infiltrating bladder urothelial carcinoma
MONDO:0004416Also known as: infiltrating bladder urothelial carcinoma, plasmacytoid variant, plasmacytoid/signet ring cell bladder carcinoma
2774 clinical trials for this condition and its sub-types, 4 tagged with Plasmacytoid variant infiltrating bladder urothelial carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Immunotherapy combo shows promise for bladder cancer patients unable to get chemo
Disease control OngoingThis early-phase trial is testing whether giving two immunotherapy drugs (durvalumab and tremelimumab) before surgery can help patients with aggressive bladder cancer who cannot take standard chemotherapy. The study involves 54 participants and primarily looks at safety and how t…
Early phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug cocktail shows promise for Hard-to-Treat urinary cancers
Disease control OngoingThis early-phase study tests a combination of two or three drugs (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced genitourinary cancers that have spread. The main goals are to find the safest doses and understand side effects. About 152 adults with vari…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat bladder cancer
Disease control OngoingThis study tests a combination of two drugs, pemetrexed and avelumab, in people with a specific type of advanced bladder cancer that lacks a protein called MTAP. The goal is to see if this treatment can shrink or control the cancer. About 18 participants who have already tried ch…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC